Adcetris and Toxic skin eruption - a phase IV clinical study of FDA data

Summary:

Toxic skin eruption is reported as a side effect among people who take Adcetris (brentuximab vedotin), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Bendamustine, and have T-cell lymphoma recurrent.

The phase IV clinical study analyzes which people have Toxic skin eruption when taking Adcetris. It is created by eHealthMe based on reports of 5,133 people who have side effects when taking Adcetris from the FDA, and is updated regularly.

What is Adcetris?

Adcetris has active ingredients of brentuximab vedotin. eHealthMe is studying from 5,136 Adcetris users. Check the latest studies of Adcetris.

What is Toxic skin eruption?

Toxic skin eruption (skin breakdown due to toxic substance) is found to be associated with 637 drugs and 1,064 conditions by eHealthMe. Check the latest studies of Toxic skin eruption.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

5,133 people reported to have side effects when taking Adcetris.
Among them, 16 people (0.31%) have Toxic skin eruption.

Could Adcetris cause Toxic skin eruption?

Among these 16 people:

How long have people been on Adcetris when they have Toxic skin eruption? *

What is the gender of people who have Toxic skin eruption when taking Adcetris? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Toxic skin eruption when taking Adcetris? *

What are other drugs people take besides Adcetris? *

What are other side effects people have besides Toxic skin eruption? *

Itching: 11 people, 68.75%
Rashes (redness): 11 people, 68.75%
Skin Hyperpigmentation (disorders affect the colour of your skin): 9 people, 56.25%
Purpura (purplish discoloration of the skin): 9 people, 56.25%
C-Reactive Protein Increased: 9 people, 56.25%
Localised Oedema (fluid retention in a particular part of the body): 9 people, 56.25%
Type Iv Hypersensitivity Reaction (delayed type hypersensitivity as the reaction takes two to three days to develop): 9 people, 56.25%
Fever: 4 people, 25.00%
Dyspnea (difficult or laboured breathing): 2 people, 12.50%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 2 people, 12.50%

What are the existing conditions these people have? *

T-Cell Lymphoma Recurrent (reoccurs a blood cell cancer): 8 people, 50.00%
Hodgkin's Lymphoma (cancer originating from white blood cells): 5 people, 31.25%
T-Cell Lymphoma (a blood cell cancer): 3 people, 18.75%
Peripheral T-Cell Lymphoma Unspecified Stage Iii (peripheral t-cell cancer unspecified stage iii): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Adcetris and have Toxic skin eruption?

- Check whether Toxic skin eruption is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adcetris:

Adcetris (5,136 reports)

Browse all side effects of Adcetris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Toxic skin eruption:

Toxic skin eruption (637 drugs)

Browse all the conditions that are associated with Toxic skin eruption:

Toxic skin eruption (1,064 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on brentuximab vedotin (the active ingredients of Adcetris) and Adcetris (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.